Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOSEPH K HAN

Allopathic & Osteopathic Physicians Otolaryngology

NPI
1760577985
CMS profile
307434
Location
NORFOLK, VA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$304,622.35

211 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
GlaxoSmithKline, LLC. $126,653.22 66
AstraZeneca Pharmaceuticals LP $64,156.86 59
GENZYME CORPORATION $45,838.12 18
Regeneron Healthcare Solutions, Inc. $19,669.69 12
Optinose US, Inc. $18,432.39 23
SANOFI US SERVICES INC. $11,950.00 2
Insmed, Inc. $11,869.65 9
Paratek Pharmaceuticals, Inc. $3,693.34 4
Medtronic, Inc. $1,460.57 9
AERIN MEDICAL INC. $497.50 4
ARS Pharmaceuticals Operations, Inc. $256.22 2
Amgen Inc. $79.55 1
Acera Surgical, Inc. $39.54 1
Merck Sharp & Dohme LLC $25.70 1

Page 4 of 5; records 151–200 of 211 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOSEPH K HAN

NPI 1760577985 · CMS profile ID 307434

Allopathic & Osteopathic Physicians / Otolaryngology

NORFOLK, VA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 5; records 151–200 of 211 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1760577985?year=2025&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOSEPH K HAN, NPI 1760577985, CMS profile ID 307434. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 5; records 151–200 of 211 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1760577985?year=2025&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). JOSEPH K HAN, NPI 1760577985, CMS profile ID 307434. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 5; records 151–200 of 211 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1760577985?year=2025&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
JOSEPH K HAN, NPI 1760577985, CMS profile ID 307434, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 5; records 151–200 of 211 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1760577985?year=2025&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

211 matching records · $304,622.35 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 211 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–200 of 211.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GENZYME CORPORATION $118.2003/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233371033 CMS
GENZYME CORPORATION $9,849.0003/19/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1233371035 CMS
GENZYME CORPORATION $512.2403/19/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1233371037 CMS
GENZYME CORPORATION $165.7103/19/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1233371039 CMS
GlaxoSmithKline, LLC. $2,400.0003/19/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1190657812 CMS
Optinose US, Inc. $123.4603/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1163263850 CMS
Optinose US, Inc. $28.0003/18/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1163263860 CMS
Optinose US, Inc. $2,100.0003/18/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1163263862 CMS
AstraZeneca Pharmaceuticals LP $2,148.0003/12/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1206643067 CMS
Optinose US, Inc. $121.8403/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1163263846 CMS
Optinose US, Inc. $13.2703/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1163263848 CMS
Optinose US, Inc. $60.3403/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1163263852 CMS
Optinose US, Inc. $981.9503/12/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1163263854 CMS
Optinose US, Inc. $1,350.0003/12/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1163263856 CMS
Optinose US, Inc. $4,500.0003/12/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1163263858 CMS
AstraZeneca Pharmaceuticals LP $805.5003/07/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1207237907 CMS
AstraZeneca Pharmaceuticals LP $402.7503/06/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1207192165 CMS
AstraZeneca Pharmaceuticals LP $12.0003/02/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1206526360 CMS
AstraZeneca Pharmaceuticals LP $359.6903/02/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1206659217 CMS
AstraZeneca Pharmaceuticals LP $50.0003/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206769792 CMS
AstraZeneca Pharmaceuticals LP $455.4003/02/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1207190295 CMS
GlaxoSmithKline, LLC. $65.7603/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190684973 CMS
GlaxoSmithKline, LLC. $92.3803/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190759601 CMS
GlaxoSmithKline, LLC. $26.6603/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191606583 CMS
Optinose US, Inc. $100.2603/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1163263842 CMS
GENZYME CORPORATION $500.0002/28/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1233371041 CMS
GENZYME CORPORATION $250.0002/28/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1233371043 CMS
Insmed, Inc. $39.9902/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186307326 CMS
Insmed, Inc. $23.9902/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186307400 CMS
Insmed, Inc. $12.0002/28/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1186307408 CMS
Insmed, Inc. $359.6902/28/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1186307412 CMS
AstraZeneca Pharmaceuticals LP $98.0202/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206431104 CMS
GlaxoSmithKline, LLC. $125.0002/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190684993 CMS
GlaxoSmithKline, LLC. $48.7502/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191426236 CMS
Insmed, Inc. $160.0802/26/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1186307348 CMS
Insmed, Inc. $500.4002/21/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1186307342 CMS
Regeneron Healthcare Solutions, Inc. $12.0002/20/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1212937288 CMS
Regeneron Healthcare Solutions, Inc. $21.8602/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212937290 CMS
Regeneron Healthcare Solutions, Inc. $2,110.5002/20/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1212937292 CMS
AstraZeneca Pharmaceuticals LP $450.0002/18/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1206419704 CMS
GlaxoSmithKline, LLC. $99.9402/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191777982 CMS
GlaxoSmithKline, LLC. $8,125.0002/07/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1191407152 CMS
Regeneron Healthcare Solutions, Inc. $5.3202/07/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1212937282 CMS
Regeneron Healthcare Solutions, Inc. $19.8102/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212937284 CMS
Regeneron Healthcare Solutions, Inc. $210.3802/07/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1212937286 CMS
GlaxoSmithKline, LLC. $12.0002/03/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1191205634 CMS
GlaxoSmithKline, LLC. $2,403.4901/31/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1190599556 CMS
GlaxoSmithKline, LLC. $4,800.0001/31/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1190641515 CMS
Optinose US, Inc. $25.6801/31/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1163263828 CMS
AERIN MEDICAL INC. $243.4801/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1249127191 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $248,445.08 287
PY2020 $106,726.25 106
PY2021 $249,544.19 215
PY2022 $253,450.75 264
PY2023 $280,830.98 236
PY2024 $352,383.35 269
PY2025 $304,622.35 211

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $8,227.19 24
PY2025 Principal investigator $144,431.92 52
PY2024 Recipient $3,808.83 6
PY2024 Principal investigator $172,361.60 48
PY2023 Recipient $2,997.04 15
PY2023 Principal investigator $109,210.23 42
PY2022 Recipient $8,000.00 21
PY2022 Principal investigator $122,231.70 32
PY2021 Recipient $10,250.00 13
PY2021 Principal investigator $148,769.04 17
PY2020 Recipient $24,660.39 29
PY2020 Principal investigator $184,768.64 20
PY2019 Recipient $7,029.41 22
PY2019 Principal investigator $178,860.59 23

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

76 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 GlaxoSmithKline, LLC. $1,011.60 12/19/2025 Non-covered Recipient Entity
EASTERN VIRGINIA MEDICAL SCHOOL
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192149191
Principal investigator 1 SANOFI US SERVICES INC. $8,689.50 12/08/2025 Non-covered Recipient Entity
Old Dominion University
A Randomized Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) No dispute reported 06/30/2026 1226087361
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,625.00 12/05/2025 Non-covered Recipient Entity
EASTERN VIRGINIA MED SCHOOL
A Randomised, Double-blind, Active-controlled 52-week Study with an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab Compared to Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis (EGPA) in Patients Receiving Standard of Care Therapy No dispute reported 06/30/2026 1185547373
Principal investigator 1 GlaxoSmithKline, LLC. $2,507.40 11/25/2025 Non-covered Recipient Entity
EASTERN VIRGINIA MEDICAL SCHOOL
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192149170
Recipient GENZYME CORPORATION $500.00 11/06/2025 Covered Recipient Physician A Randomized Double-blind Placebo-controlled Parallel Group Study Assessing the Efficacy and Safety of Dupilumab in Patients With Allergic Fungal Rhinosinusitis (AFRS) No dispute reported 06/30/2026 1226120015
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $573.75 11/03/2025 Non-covered Recipient Entity
EASTERN VIRGINIA MEDICAL SCHOOL
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184256953
Principal investigator 1 SANOFI US SERVICES INC. $3,299.00 10/20/2025 Non-covered Recipient Entity
Old Dominion University
A Randomized Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) No dispute reported 06/30/2026 1226087303
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $573.75 10/03/2025 Non-covered Recipient Entity
EASTERN VIRGINIA MEDICAL SCHOOL
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184245231
Principal investigator 1 GlaxoSmithKline, LLC. $1,504.80 10/02/2025 Non-covered Recipient Entity
EASTERN VIRGINIA MEDICAL SCHOOL
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192184807
Principal investigator 1 SANOFI US SERVICES INC. $6,146.50 09/22/2025 Non-covered Recipient Entity
Old Dominion University
A Randomized Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) No dispute reported 06/30/2026 1226087278
Principal investigator 1 GlaxoSmithKline, LLC. $1,082.70 09/03/2025 Non-covered Recipient Entity
EASTERN VIRGINIA MEDICAL SCHOOL
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192149174
Principal investigator 1 SANOFI US SERVICES INC. $16,128.00 08/25/2025 Non-covered Recipient Entity
Old Dominion University
A Randomized, Double-blind, Placebo-controlled, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab in Participants With Inadequately Controlled Chronic Rhinosinusitis Without Nasal Polyps No dispute reported 06/30/2026 1226087263
Principal investigator 1 SANOFI US SERVICES INC. $19,128.00 08/18/2025 Non-covered Recipient Entity
Old Dominion University
A Randomized Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) No dispute reported 06/30/2026 1226087258
Principal investigator 1 GlaxoSmithKline, LLC. $422.10 08/04/2025 Non-covered Recipient Entity
EASTERN VIRGINIA MEDICAL SCHOOL
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192149187
Principal investigator 1 GlaxoSmithKline, LLC. $1,244.70 07/23/2025 Non-covered Recipient Entity
EASTERN VIRGINIA MEDICAL SCHOOL
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192184818
Principal investigator 1 SANOFI US SERVICES INC. $13,840.00 07/14/2025 Non-covered Recipient Entity
Old Dominion University
A Randomized Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) No dispute reported 06/30/2026 1226087230
Principal investigator 1 GlaxoSmithKline, LLC. $1,000.00 06/22/2025 Non-covered Recipient Entity
EASTERN VIRGINIA MEDICAL SCH
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP PHASE III STUDY TO ASSESS T No dispute reported 06/30/2026 1192182778
Principal investigator 1 GlaxoSmithKline, LLC. $200.00 06/22/2025 Non-covered Recipient Entity
EASTERN VIRGINIA MEDICAL SCH
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP PHASE III STUDY TO ASSESS T No dispute reported 06/30/2026 1192182786
Principal investigator 1 GlaxoSmithKline, LLC. $1,500.00 06/22/2025 Non-covered Recipient Entity
EASTERN VIRGINIA MEDICAL SCH
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP PHASE III STUDY TO ASSESS T No dispute reported 06/30/2026 1192182790
Principal investigator 1 GlaxoSmithKline, LLC. $1,360.00 06/22/2025 Non-covered Recipient Entity
EASTERN VIRGINIA MEDICAL SCH
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP PHASE III STUDY TO ASSESS T No dispute reported 06/30/2026 1192182795
Principal investigator 1 GlaxoSmithKline, LLC. $1,082.70 06/20/2025 Non-covered Recipient Entity
EASTERN VIRGINIA MEDICAL SCHOOL
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192149183
Recipient GlaxoSmithKline, LLC. $28.15 06/19/2025 Covered Recipient Physician THE IMAGINE STUDY: A PHASE 3B OPEN LABEL, SINGLE ARM STUDY TO ASSESS T No dispute reported 06/30/2026 1192182800
Recipient GlaxoSmithKline, LLC. $18.13 06/19/2025 Covered Recipient Physician THE IMAGINE STUDY: A PHASE 3B OPEN LABEL, SINGLE ARM STUDY TO ASSESS T No dispute reported 06/30/2026 1192182803
Recipient GlaxoSmithKline, LLC. $171.47 06/19/2025 Covered Recipient Physician THE IMAGINE STUDY: A PHASE 3B OPEN LABEL, SINGLE ARM STUDY TO ASSESS T No dispute reported 06/30/2026 1192182808
Recipient GlaxoSmithKline, LLC. $76.71 06/19/2025 Covered Recipient Physician THE IMAGINE STUDY: A PHASE 3B OPEN LABEL, SINGLE ARM STUDY TO ASSESS T No dispute reported 06/30/2026 1192184788
Recipient GlaxoSmithKline, LLC. $128.47 06/19/2025 Covered Recipient Physician THE IMAGINE STUDY: A PHASE 3B OPEN LABEL, SINGLE ARM STUDY TO ASSESS T No dispute reported 06/30/2026 1192184792
Recipient GlaxoSmithKline, LLC. $64.27 06/19/2025 Covered Recipient Physician THE IMAGINE STUDY: A PHASE 3B OPEN LABEL, SINGLE ARM STUDY TO ASSESS T No dispute reported 06/30/2026 1192184796
Recipient GlaxoSmithKline, LLC. $102.09 06/19/2025 Covered Recipient Physician THE IMAGINE STUDY: A PHASE 3B OPEN LABEL, SINGLE ARM STUDY TO ASSESS T No dispute reported 06/30/2026 1192184800
Recipient GlaxoSmithKline, LLC. $888.81 06/19/2025 Covered Recipient Physician THE IMAGINE STUDY: A PHASE 3B OPEN LABEL, SINGLE ARM STUDY TO ASSESS T No dispute reported 06/30/2026 1192184803
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $573.75 06/18/2025 Non-covered Recipient Entity
EASTERN VIRGINIA MEDICAL SCHOOL
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184207861
Recipient SANOFI US SERVICES INC. $385.40 06/06/2025 Covered Recipient Physician A randomized, double-blind, placebo-controlled, parallel-group, 52-week Phase 3 trial to investigate the efficacy, safety, and tolerability of itepekimab in adult participants with inadequately-controlled chronic rhinosinusitis with nasal polyps No dispute reported 06/30/2026 1226119947
Recipient SANOFI US SERVICES INC. $652.80 06/06/2025 Covered Recipient Physician A randomized, double-blind, placebo-controlled, parallel-group, 52-week Phase 3 trial to investigate the efficacy, safety, and tolerability of itepekimab in adult participants with inadequately-controlled chronic rhinosinusitis with nasal polyps No dispute reported 06/30/2026 1226119952
Recipient SANOFI US SERVICES INC. $267.70 06/06/2025 Covered Recipient Physician A randomized, double-blind, placebo-controlled, parallel-group, 52-week Phase 3 trial to investigate the efficacy, safety, and tolerability of itepekimab in adult participants with inadequately-controlled chronic rhinosinusitis with nasal polyps No dispute reported 06/30/2026 1226119956
Recipient SANOFI US SERVICES INC. $50.00 06/06/2025 Covered Recipient Physician A randomized, double-blind, placebo-controlled, parallel-group, 52-week Phase 3 trial to investigate the efficacy, safety, and tolerability of itepekimab in adult participants with inadequately-controlled chronic rhinosinusitis with nasal polyps No dispute reported 06/30/2026 1226119962
Recipient SANOFI US SERVICES INC. $85.00 06/06/2025 Covered Recipient Physician A randomized, double-blind, placebo-controlled, parallel-group, 52-week Phase 3 trial to investigate the efficacy, safety, and tolerability of itepekimab in adult participants with inadequately-controlled chronic rhinosinusitis with nasal polyps No dispute reported 06/30/2026 1226119967
Recipient SANOFI US SERVICES INC. $69.81 06/06/2025 Covered Recipient Physician A randomized, double-blind, placebo-controlled, parallel-group, 52-week Phase 3 trial to investigate the efficacy, safety, and tolerability of itepekimab in adult participants with inadequately-controlled chronic rhinosinusitis with nasal polyps No dispute reported 06/30/2026 1226119972
Recipient SANOFI US SERVICES INC. $200.17 06/05/2025 Covered Recipient Physician A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Phase 3 Trial to Investigate the Efficacy, Safety, and Tolerability of Itepekimab in Adult Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps No dispute reported 06/30/2026 1226119958
Principal investigator 1 GlaxoSmithKline, LLC. $422.10 05/21/2025 Non-covered Recipient Entity
EASTERN VIRGINIA MEDICAL SCHOOL
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192149179
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $573.75 05/19/2025 Non-covered Recipient Entity
EASTERN VIRGINIA MEDICAL SCHOOL
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184196995
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $573.75 05/19/2025 Non-covered Recipient Entity
EASTERN VIRGINIA MEDICAL SCHOOL
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184196997
Principal investigator 1 GlaxoSmithKline, LLC. $1,244.70 04/23/2025 Non-covered Recipient Entity
EASTERN VIRGINIA MEDICAL SCHOOL
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192184822
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $573.75 04/23/2025 Non-covered Recipient Entity
EASTERN VIRGINIA MEDICAL SCHOOL
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184186031
Principal investigator 1 SANOFI US SERVICES INC. $11,414.46 04/21/2025 Non-covered Recipient Entity
Eastern Virginia Medical School Department Of Internal Medicine
A Randomized, Double-blind, Placebo-controlled, 2-part Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Uncontrolled, Chronic Rhinosinusitis Without Nasal Polyposis (CRSsNP) No dispute reported 06/30/2026 1226080661
Principal investigator 1 SANOFI US SERVICES INC. $1,610.00 04/07/2025 Non-covered Recipient Entity
Eastern Virginia Medical School Department Of Internal Medicine
A Randomized Double-blind Placebo-controlled Parallel Group Study Assessing the Efficacy and Safety of Dupilumab in Patients With Allergic Fungal Rhinosinusitis (AFRS) No dispute reported 06/30/2026 1226080648
Recipient SANOFI US SERVICES INC. $788.36 04/04/2025 Covered Recipient Physician A Randomized, Double-blind, Placebo-controlled, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab in Participants With Inadequately Controlled Chronic Rhinosinusitis Without Nasal Polyps No dispute reported 06/30/2026 1226119976
Recipient SANOFI US SERVICES INC. $395.38 04/04/2025 Covered Recipient Physician A Randomized, Double-blind, Placebo-controlled, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab in Participants With Inadequately Controlled Chronic Rhinosinusitis Without Nasal Polyps No dispute reported 06/30/2026 1226119980
Recipient SANOFI US SERVICES INC. $395.50 04/04/2025 Covered Recipient Physician A Randomized, Double-blind, Placebo-controlled, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab in Participants With Inadequately Controlled Chronic Rhinosinusitis Without Nasal Polyps No dispute reported 06/30/2026 1226119983
Recipient SANOFI US SERVICES INC. $81.75 04/04/2025 Covered Recipient Physician A Randomized, Double-blind, Placebo-controlled, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab in Participants With Inadequately Controlled Chronic Rhinosinusitis Without Nasal Polyps No dispute reported 06/30/2026 1226119987
Recipient SANOFI US SERVICES INC. $21.80 04/04/2025 Covered Recipient Physician A Randomized, Double-blind, Placebo-controlled, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab in Participants With Inadequately Controlled Chronic Rhinosinusitis Without Nasal Polyps No dispute reported 06/30/2026 1226119990
Recipient SANOFI US SERVICES INC. $275.12 03/03/2025 Covered Recipient Physician A Randomized Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) No dispute reported 06/30/2026 1226119922
Recipient SANOFI US SERVICES INC. $536.15 03/03/2025 Covered Recipient Physician A Randomized Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) No dispute reported 06/30/2026 1226119926
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $215.16 02/27/2025 Non-covered Recipient Entity
EASTERN VIRGINIA MEDICAL SCHOOL
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184156040
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $215.16 02/27/2025 Non-covered Recipient Entity
EASTERN VIRGINIA MEDICAL SCHOOL
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184156042
Principal investigator 1 GlaxoSmithKline, LLC. $1,082.70 02/25/2025 Non-covered Recipient Entity
EASTERN VIRGINIA MEDICAL SCHOOL
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192184810
Principal investigator 1 GENZYME CORPORATION $3,029.60 02/10/2025 Non-covered Recipient Entity
Eastern Virginia Medical School Department Of Internal Medicine
A Randomized, Double-blind, Head-to-head Comparison of Dupilumab Versus Omalizumab in Severe Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) and Comorbid Asthma Patients No dispute reported 06/30/2026 1226080652
Principal investigator 1 GENZYME CORPORATION $3,000.00 02/10/2025 Non-covered Recipient Entity
Eastern Virginia Medical School Department Of Internal Medicine
A Randomized, Double-blind, Head-to-head Comparison of Dupilumab Versus Omalizumab in Severe Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) and Comorbid Asthma Patients No dispute reported 06/30/2026 1226080657
Principal investigator 1 SANOFI US SERVICES INC. $2,898.43 02/10/2025 Non-covered Recipient Entity
Eastern Virginia Medical School Department Of Internal Medicine
A Randomized Double-blind Placebo-controlled Parallel Group Study Assessing the Efficacy and Safety of Dupilumab in Patients With Allergic Fungal Rhinosinusitis (AFRS) No dispute reported 06/30/2026 1226080637
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $573.75 02/05/2025 Non-covered Recipient Entity
EASTERN VIRGINIA MEDICAL SCHOOL
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184152228
Principal investigator 1 AstraZeneca Pharmaceuticals LP $14,429.83 01/31/2025 Non-covered Recipient Entity
EASTERN VIRGINIA MED SCHOOL
A Multicenter Randomized Double Blind Parallel Group Placebo Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Patients with Severe Chronic Rhinosinusitis with Nasal Polyposis WAYPOINT No dispute reported 06/30/2026 1185547371
Principal investigator 1 GlaxoSmithKline, LLC. $3,700.68 01/31/2025 Non-covered Recipient Entity
EASTERN VIRGINIA MEDICAL SCH
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP PHASE III STUDY TO ASSESS T No dispute reported 06/30/2026 1192182782
Principal investigator 1 SANOFI US SERVICES INC. $4,198.75 01/27/2025 Non-covered Recipient Entity
Eastern Virginia Medical School Department Of Internal Medicine
A Randomized, Double-blind, Placebo-controlled, 2-part Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Uncontrolled, Chronic Rhinosinusitis Without Nasal Polyposis (CRSsNP) No dispute reported 06/30/2026 1226080640
Principal investigator 1 SANOFI US SERVICES INC. $2,790.00 01/27/2025 Non-covered Recipient Entity
Eastern Virginia Medical School Department Of Internal Medicine
A Randomized, Double-blind, Placebo-controlled, 2-part Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Uncontrolled, Chronic Rhinosinusitis Without Nasal Polyposis (CRSsNP) No dispute reported 06/30/2026 1226080644
Principal investigator 1 GlaxoSmithKline, LLC. $1,752.30 01/24/2025 Non-covered Recipient Entity
EASTERN VIRGINIA MEDICAL SCHOOL
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192149166
Principal investigator 1 GlaxoSmithKline, LLC. $1,875.00 01/08/2025 Non-covered Recipient Entity
EASTERN VIRGINIA MEDICAL SCHOOL
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192184814
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $561.60 01/02/2025 Non-covered Recipient Entity
EASTERN VIRGINIA MEDICAL SCHOOL
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184144688
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $770.00 01/02/2025 Non-covered Recipient Entity
EASTERN VIRGINIA MEDICAL SCHOOL
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184144690
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $462.00 01/02/2025 Non-covered Recipient Entity
EASTERN VIRGINIA MEDICAL SCHOOL
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184144692
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $280.80 01/02/2025 Non-covered Recipient Entity
EASTERN VIRGINIA MEDICAL SCHOOL
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184144694
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $462.00 01/02/2025 Non-covered Recipient Entity
EASTERN VIRGINIA MEDICAL SCHOOL
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184144696
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $539.00 01/02/2025 Non-covered Recipient Entity
EASTERN VIRGINIA MEDICAL SCHOOL
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184144698
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $539.00 01/02/2025 Non-covered Recipient Entity
EASTERN VIRGINIA MEDICAL SCHOOL
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184144700
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.40 01/02/2025 Non-covered Recipient Entity
EASTERN VIRGINIA MEDICAL SCHOOL
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184144702
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $308.00 01/02/2025 Non-covered Recipient Entity
EASTERN VIRGINIA MEDICAL SCHOOL
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184144704
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $351.00 01/02/2025 Non-covered Recipient Entity
EASTERN VIRGINIA MEDICAL SCHOOL
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184144706
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $351.00 01/02/2025 Non-covered Recipient Entity
EASTERN VIRGINIA MEDICAL SCHOOL
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184144708
Recipient Regeneron Pharmaceuticals, Inc. $2,044.15 01/01/2025 Covered Recipient Physician DUPIXENT CLINICAL DEVELOPMENT PROGRAM No dispute reported 06/30/2026 1184118185